Assessing Resistance Costs of Antiretroviral Therapies via Measures of Future Drug Options

Journal of Infectious Diseases

Volumn 188, Issue 7, 2003, Pages 1001-1008

  Jiang, Hongyu ^a   Deeks, Steven G ^d   Kuritzkes, Daniel R ^b   Lallemant, Marc ^f   Katzenstein, David ^e   Albrecht, Mary ^c   DeGruttola, Victor ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD UNIVERSITY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NELFINAVIR; NUCLEOSIDE ANALOG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROSS RESISTANCE; DATA ANALYSIS; DRUG CLASSIFICATION; DRUG EFFICACY; EVALUATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIRUS MUTATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MODELS, STATISTICAL; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 0142010633     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/378355     Document Type: Article

References (42)

1. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7.
2. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8.
3. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society - USA Panel. JAMA 2002; 288:222-35.
4. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. The Panel on Clinical Practices for the Treatment of HIV. Ann Intern Med 2002; 137(5 Pt. 2):381-433.
5. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001; 2:276-313.
6. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2:760-6.
7. Harrigan PR, Larder BA. Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates. Antimicrob Agents Chemother 2002; 46:909-12.
8. Hammer SM, Vaida F, Bennett KK, et al. Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002; 288:169-80.
9. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis 2000; 182:1375-84.
10. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-53.
11. + cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis 2002; 185:471-80.
12. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-80.
13. Barbour J, Wrin T, Grant R, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in HIV-infected adults. J Virol 2002; 76:11104-12.
14. The HIV/AIDS situation in the world. ONUSIDA/01.75F WHO/CDS/ NCS/2001.2. December 2001.
15. United Nations. Declaration of Commitment on HIV/AIDS. A/RES/ S-26/2. August 2001.
16. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-8.
17. Gilbert PB, Hanna GJ, De Gruttola V, et al. Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens. AIDS Res Hum Retroviruses 2000; 16:1325-36.
18. Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001; 345:398-407.
19. Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/mL receiving combination therapy. JAMA 2001; 286:196-207.
20. Huang Y. The two-sample problem with induced dependent censorship. Biometrics 1999;55:1108-13.
21. Zhao H, Tsiatis AA. Estimating mean quality adjusted lifetime with censored data. Sankhya, Series B, Indian Journal of Statistics 2000; 62:175-88.
22. Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika 2000; 87:329-43.
23. Kantor R, Machekano R, Gonzales MJ, Dupnik K, Schapiro JM, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res 2001; 29:296-9.
24. Winters MA, Bosch RJ, Albrecht MA, Katzenstein DA. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment [abstract 122]. ACTG 364 Study Team. In: Program and abstracts of the XI International HIV Drug Resistance Workshop (Seville, Spain). Antivir Ther 2002;7(Suppl 1):S134.
25. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33.
26. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194-9.
27. Gilbert PB, Ribaudo HJ, Greenberg L, et al. Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial. AIDS 2000; 14:1961-72.
28. Carr A. Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy. Lancet 2002; 360:81-5.
29. + lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997; 126:929-38.
30. Katzenstein D, Downey G, Bosch R, Hellmann N, Becker M, Albrecht M. Evolution of protease phenotype and genotype changes at initial and continued virologic failure among nucleoside-experienced subjects receiving nelfinavir (NFV) in ACTG 364 [abstract 144]. ACTG 364 Virology team. In: Program and abstracts of the XI International HIV Drug Resistance Workshop (Seville, Spain). Antivir Ther 2002;7(Suppl 1):S156.
31. Tebas P, Patick AK, Kane EM, et al. Virologic responses to a ritonavirsaquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999; 13:F23-8.
32. Kemper CA, Witt MD, Reiser PH, et al. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS 2001; 15:609-15.
33. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA Panel. JAMA 2000; 283:2417-26.
34. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 1998; 280:35-41.
35. Martinez-Picado J, Morales-Lopetegi K, Wrin T, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002; 16:895-9.
36. Rabkin M, El-Sadr W, Katzenstein D, et al. Antiretroviral therapy in resource-poor settings: clinical research priorities. Lancet 2002; 360: 1503-5.
37. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340:1605-13.
38. Zhang L, Chung C, Hu BS, et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 2000; 106:839-45.
39. Ait-Khaled M, Stone C, Amphlett G, et al. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002; 16:1686-9.
40. Markland W, Rao BG, Parsons JD, et al. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir. J Virol 2000; 74:7636-41.
41. Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS 2003; 17:821-30.
42. Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther 2001; 6:115-26.